• L Provinciali, S Lattanzi, R Chiarlone, A Fogliardi, F Intelligente, C Irace, M Lanzilotta, R Palomba, E Storelli, and M Zampi.
• Clinica Neurologica, Dipartimento di Medicina Sperimentale e Clinica, Università Politecnica delle Marche Ancona, Italia - l.provinciali@univpm.it.
• Minerva Med. 2014 Dec 1;105(6):515-27.

AbstractThe treatment of neuropathic pain is a medical challenge. The responsiveness to the different classes of drugs is often unsatisfactory and frequently associated to a wide range of side effects. International guidelines suggest for the "localized" neuropathic pain the topical treatment with 5% lidocaine medicated plaster, alone or associated to systemic drugs, as the first choice since its favorable efficacy and tolerability profile. Many clinical experiences support the rationale for using 5% lidocaine medicated plaster in different kinds of localized neuropathic pain, such as postherpetic and trigeminal neuralgia, compressive syndromes, painful diabetic polyneuropathy and pain secondary to trauma or surgical interventions. This paper reports a series of clinical cases whose heterogeneity suggests the wide burden of applicability of the topical 5% lidocaine, either alone and associated to systemic drugs. All the described conditions were characterized by a highly intense pain, not adequately controlled by actual medications, which improved after the use of topical lidocaine. The good response to lidocaine allowed the reduction, of even the withdrawal, of concurrent drugs and improved the patients' quality of life.

63 keywords...

hide…